Unichem Laboratories Ltd Stock Falls to 52-Week Low of Rs.315.6

Recent Price Movement and Market Context

On the day the new low was recorded, Unichem Laboratories opened sharply lower by 4.51%, continuing a four-day losing streak that has seen the stock shed 9.27% in value. The intraday low of Rs.315.6 represents a substantial decline from its 52-week high of Rs.727.95, underscoring the extent of the recent sell-off. The stock’s performance today also lagged the Pharmaceuticals & Biotechnology sector by 0.52%, while broader market sentiment was mixed with the Sensex recovering some losses to trade at 78,851.05, down 1.73% for the day.

Technically, Unichem Laboratories is trading below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend. This contrasts with the Sensex, which, despite trading below its 50-day moving average, maintains a 50DMA above its 200DMA, indicating a more stable medium-term outlook for the benchmark index.

Financial Performance and Profitability Concerns

Unichem Laboratories’ financial results have contributed to the subdued market sentiment. The company reported a Profit Before Tax excluding other income (PBT LESS OI) of Rs.6.11 crores in the latest quarter, a sharp decline of 77.2% compared to the previous four-quarter average. Net profit (PAT) also fell by 56.0% to Rs.16.13 crores over the same period. Meanwhile, interest expenses have increased by 30.5% in the last six months, reaching Rs.15.66 crores, reflecting rising financing costs.

Over the past year, the stock has delivered a negative return of 48.70%, significantly underperforming the Sensex’s positive 8.02% gain. The company’s long-term growth has been modest, with net sales growing at an annualised rate of 11.95% over the last five years. Return on Equity (ROE) remains low at an average of 1.44%, indicating limited profitability relative to shareholders’ funds.

Debt Levels and Valuation Metrics

One of the key factors weighing on Unichem Laboratories is its elevated leverage. The company’s Debt to EBITDA ratio stands at 4.87 times, indicating a relatively high debt burden compared to earnings before interest, taxes, depreciation, and amortisation. This ratio suggests a constrained ability to service debt efficiently, which may be a concern for creditors and investors alike.

Despite these challenges, the company’s operating profit has shown robust long-term growth, expanding at an annual rate of 148.09%. Additionally, Unichem Laboratories maintains a Return on Capital Employed (ROCE) of 4.9%, which, while modest, contributes to a valuation that is considered very attractive. The enterprise value to capital employed ratio is close to 1, signalling that the stock is trading at a discount relative to its capital base.

Further, the company’s Price/Earnings to Growth (PEG) ratio is 0.7, reflecting a valuation that is low relative to its profit growth of 29.9% over the past year. This suggests that the market is pricing in significant risks or uncertainties despite some positive earnings momentum.

Shareholding and Market Position

The majority ownership of Unichem Laboratories remains with promoters, which can provide a degree of stability in governance and strategic direction. However, the stock’s Mojo Score of 31.0 and a Mojo Grade of Sell, upgraded from a previous Strong Sell on 16 Feb 2026, reflect ongoing concerns about the company’s near-term prospects and financial health.

In terms of relative performance, Unichem Laboratories has underperformed the BSE500 index over the last three years, one year, and three months, indicating persistent challenges in maintaining competitive momentum within the Pharmaceuticals & Biotechnology sector.

Summary of Key Metrics

To summarise, Unichem Laboratories Ltd’s stock has reached a new 52-week low of Rs.315.6 after a sustained period of decline. The company faces challenges including a high Debt to EBITDA ratio of 4.87 times, subdued profitability with an average ROE of 1.44%, and a significant drop in quarterly profits. While operating profit growth and valuation metrics such as ROCE and PEG ratio offer some positive context, the overall market response has been cautious, reflected in the stock’s underperformance relative to sector peers and the broader market.

These factors collectively contribute to the current market valuation and sentiment surrounding Unichem Laboratories, as the stock trades well below all major moving averages and continues to navigate a challenging environment within the Pharmaceuticals & Biotechnology sector.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today